Hamilton, ON (July 23, 2025) — Insight Medbotics, an interventional oncology company advancing precision in cancer care through its MRI-compatible robotics, is pleased to announce that Dr. Edward Matsumoto, a urology expert whose clinical practice uses advanced, minimally-invasive approaches in urologic surgery, has joined the company’s Board of Directors.
While MRI is the gold standard for visualizing soft-tissue cancers and is commonly used for diagnostic scans, this imaging technology isn’t widely used to perform cancer interventions, such as taking biopsies or in other treatments. Insight Medbotics is developing a new robotics category designed for use with MRI to help solve this access challenge. The IGAR system has been clinically demonstrated in breast cancer patients and is the world’s first and only FDA-cleared, MRI-compatible robot.
With a FDA 510(k) clearance in breast biopsy, Insight Medbotics envisions development in other biopsies, therapy delivery, and device placement. Prostate cancer, which still relies on imprecise biopsy methodologies and radical whole gland treatment, is the next patient care area where the IGAR robotics technology could play a leading role in delivering greater precision, better economics, and an improved patient experience.
Dr. Matsumoto, M.D., M. Ed., F.R.C.S.C., is a staff urologist at the McMaster Institute of Urology, which is part of St. Joseph’s Healthcare in Hamilton, ON. He specializes in minimally invasive approaches to radical prostatectomy, such as laparoscopic and robotically assisted laparoscopic techniques, which result in decreased morbidity in contrast to open surgical practices.
Dr. Matsumoto completed medical school, residency, and his master’s degree in Health Education at the University of Toronto. He then completed a fellowship in Laparoscopy and Endourology at the University of Texas Southwestern Medical Centre in Dallas, Texas. Dr. Matsumoto is currently associate professor of Surgery at McMaster University, where he teaches advanced techniques such as minimally invasive radical prostatectomy to clinical fellows and applies them to his practice. He has also authored numerous peer-reviewed publications and is among the first urologists in Ontario to perform Greenlight laser ablation on prostates. His research interests in surgical education includes simulator and robotic training, surgical training methods, and technical skills assessment.
“As a urologist, I’m excited about Insight Medbotics’ approach to combining minimally invasive surgery with MR imaging and artificial intelligence tools. I seek innovations that promise to benefit my patients, and I appreciate their intelligent approach to targeting cancer, the advanced state of their beta device, and how intuitive their software is to use. Joining the board offers influence over this promising technology’s evolution and the less invasive procedures that could benefit prostate cancer patients while advancing a made-in-Canada solution.”
~ Edward Matsumoto, member of the Board of Directors, Insight Medbotics
“Opportunities to work with clinicians and patients whose needs drive our design decisions is a tremendous gift. Dr. Edward Matsumoto is a key opinion leader and prolific innovator seeking to advance the standard of care for urology patients through new technology and surgical education. I’m honoured that he shares our excitement about the potential MRI-compatible robotics hold for advancing precision in prostate cancer care. On behalf of Chair Dean Mosca, the board of directors, and the entire company, I look forward to working with Edward.”
~ Fazila Seker, CEO of Insight Medbotics and member of the Board of Directors
